Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 09 - 28 symbols : LLY save search
FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy
Published: 2021-09-28 (Crawled : 22:00) - prnewswire.com
PFE A | $25.39 -0.12% 0.24% 31M
|
Health Technology
|
| O: 0.42%
H: 1.09%
C: 0.72%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 1.72%
H: 2.68%
C: 2.2%
treatment fda positive therapy cancer colorectal cancer
F-Secure Becomes Cybersecurity Awareness Month 2021 Champion
Published: 2021-09-28 (Crawled : 15:00) - prnewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
MAR | $236.3 -0.91% -0.93% 1.8M
|
Consumer Services
|
| O: -0.77%
H: 1.42%
C: 0.3%
security cybersecurity
Care Access and Eli Lilly and Company Partner to Increase Diversity Within Oncology Clinical Trials
Published: 2021-09-28 (Crawled : 14:15) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
clinical trials trials trial
Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder
Published: 2021-09-28 (Crawled : 12:15) - biospace.com/
NVO | $122.75 -1.43% 0.65% 2.7M
|
Health Technology
|
| O: -2.48%
H: 0.0%
C: -1.28%
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
ALNY | News | $145.16 -0.11% -0.19% 400K
|
Health Technology
|
| O: -7.01%
H: 2.22%
C: -1.77%
alcohol use disorder treatment phase 1 trial
Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options
Published: 2021-09-28 (Crawled : 12:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
ford test injection insulin
UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions
Published: 2021-09-28 (Crawled : 07:00) - prnewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
collaboration license
Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions
Published: 2021-09-28 (Crawled : 00:00) - prnewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.0%
H: 0.0%
C: -2.12%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -0.27%
H: 0.81%
C: -0.56%
collaboration license
Gainers vs Losers
| 60% | 40% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.